By any measure, 2025 was a landmark year for Cibus, Inc., not because of any single headline, but because of a convergence of key themes that are shaping the trajectory of the gene editing industry.

Good afternoon, and thank you for joining today's conference call. To discuss Peraso Inc.'s fourth quarter and full year 2025 financial results. The press release and Form 8-Ks are available on Peraso ...